Prognostic implications of PD-L1 expression in patients with angiosarcoma

Jii Bum Lee; Beung-Chul Ahn; Seung Hyun Kim; Young Han Lee; Jung Woo Han; Min Kyung Jeon; Soo Hee Kim; Hyo Song Kim

doi:10.2144/fsoa-2020-0211

Prognostic implications of PD-L1 expression in patients with angiosarcoma

Future Sci OA. 2021 Mar 2;7(5):FSO691. doi: 10.2144/fsoa-2020-0211.

Authors

Jii Bum Lee¹, Beung-Chul Ahn¹, Seung Hyun Kim², Young Han Lee³, Jung Woo Han⁴, Min Kyung Jeon¹, Soo Hee Kim⁵, Hyo Song Kim¹

Affiliations

¹ Department of Internal Medicine, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
² Department of Orthopedic Surgery, Yonsei University College of Medicine, Seoul, Korea.
³ Department of Radiology, Yonsei University College of Medicine, Seoul, Korea.
⁴ Department of Pediatric Hemato-Oncology, Yonsei University College of Medicine, Seoul, Korea.
⁵ Pathology Center, Seegene Medical Foundation, Seoul, Korea.

Abstract

Aim: There are limited data on the feasibility of programmed death ligand-1 (PD-L1) expression as a prognostic biomarker in metastatic angiosarcoma.

Patients & methods: We retrospectively collected and analyzed the data on PD-L1 expression in 70 angiosarcoma patients who were diagnosed at our center between 2005 and 2019.

Results: Thirteen (19%) patients had PD-L1 expression. Metastatic angiosarcoma patients who were PD-L1-negative (n = 24) showed longer median progression-free survival (4.9 vs 1.6 months; p = 0.04) and median overall survival (OS; 10.9 vs 5.4 months; p = 0.01) than those who were PD-L1-positive (n = 4). PD-L1 status proved to be a significant factor for OS.

Conclusion: Metastatic angiosarcoma patients with PD-L1 expression showed shorter survival. PD-L1 status is an independent prognostic factor for OS in metastatic angiosarcoma patients.

Keywords: PD-L1; angiosarcoma; chemotherapy; overall survival; prognosis.